Search

Roche Holding AG

Chiusa

SettoreSettore sanitario

283.2 -0.07

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

279.6

Massimo

286

Metriche Chiave

By Trading Economics

Entrata

1.7B

3.7B

Vendite

-15B

16B

P/E

Media del settore

25.123

37.461

Rendimento da dividendi

3.28

Margine di Profitto

23.266

Dipendenti

103,249

EBITDA

547M

6.5B

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.28%

2.33%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

22B

227B

Apertura precedente

283.27

Chiusura precedente

283.2

Roche Holding AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 ott 2025, 09:32 UTC

Utili

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 ott 2025, 05:54 UTC

Utili

Roche Raises Full-Year Earnings Outlook

1 ott 2025, 08:54 UTC

I principali Market Mover

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 set 2025, 14:01 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18 set 2025, 10:05 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

89bio Shares Soar Premarket on Takeover by Roche

18 set 2025, 10:04 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18 set 2025, 05:37 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy 89bio for Up to $3.5 Billion

23 ott 2025, 09:19 UTC

Discorsi di Mercato
Utili

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 ott 2025, 09:11 UTC

Discorsi di Mercato
Utili

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 ott 2025, 05:09 UTC

Utili

Roche 3Q Sales Up 6% At CER

23 ott 2025, 05:07 UTC

Utili

Roche 3Q Sales CHF14.92B

23 ott 2025, 05:07 UTC

Utili

Analysts Had Seen 3Q Sales At CHF15.17B

23 ott 2025, 05:07 UTC

Utili

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 ott 2025, 05:05 UTC

Utili

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

23 ott 2025, 05:04 UTC

Utili

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

23 ott 2025, 05:02 UTC

Utili

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

23 ott 2025, 05:02 UTC

Utili

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

23 ott 2025, 05:02 UTC

Utili

Roche 9-Mos CH45.9B

23 ott 2025, 05:01 UTC

Utili

Roche Raises 2025 View

1 ott 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 ott 2025, 09:05 UTC

Azioni calde

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18 set 2025, 14:12 UTC

Acquisizioni, Fusioni, Takeovers

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18 set 2025, 07:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18 set 2025, 05:09 UTC

Acquisizioni, Fusioni, Takeovers

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18 set 2025, 05:06 UTC

Acquisizioni, Fusioni, Takeovers

Roche: Deal Is Expected to Close in 4Q

18 set 2025, 05:06 UTC

Acquisizioni, Fusioni, Takeovers

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18 set 2025, 05:05 UTC

Acquisizioni, Fusioni, Takeovers

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18 set 2025, 05:05 UTC

Acquisizioni, Fusioni, Takeovers

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18 set 2025, 05:04 UTC

Acquisizioni, Fusioni, Takeovers

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18 set 2025, 05:03 UTC

Acquisizioni, Fusioni, Takeovers

Roche: Total Deal Value Is Up to $3.5B

Roche Holding AG Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat